KLOW 80mg (Pen)
80 mg
$349.99 CAD
GHRH analogue · Research reagent
A hormone-signalling peptide studied in clinical trials involving adults with HIV-related abdominal fat accumulation. Researchers measured internal abdominal fat and growth-related markers.
$156.99 CAD
· $15.70 / mgIn stockSample 5026_0273 · 100.00% purity
PPB Analytical Inc. · View report
In stock · Ships next business day from Toronto
Interac e-Transfer
$9.99 shipping, free from $250 · Ships from Toronto · Canada only
Shipping and returns: Ships next business day from Toronto · $9.99 shipping, free from $250 · Arrives right or we make it right
For research use only. Not for human consumption.
Proof Line vials are filled from Align Biosciences stock under the Proof Line label. This is Align’s independent lab report for Tesamorelin 10 mg. The report records a laboratory sample ID; a production lot number is shown when the report includes one.
Proof Line vials are filled from Align Biosciences stock under the Proof Line label. This is Align’s independent lab report for Tesamorelin 10 mg. The report records a laboratory sample ID; a production lot number is shown when the report includes one.
Tesamorelin, also published as TH9507, is catalogued here as: GHRH analogue, growth-axis research. Studied in adults with HIV-associated abdominal fat accumulation for imaging-measured visceral fat and hormone changes. Tesamorelin is described as an analogue of growth hormone-releasing hormone (GHRH), also called growth hormone-releasing factor (GRF). It prompts the body’s own growth-hormone signalling rather than being administered growth hormone, which is why IGF-I is measured as part of the studied response. A hormone-signalling peptide studied in clinical trials involving adults with HIV-related abdominal fat accumulation. Researchers measured internal abdominal fat and growth-related markers.
The relevant clinical research measured visceral adipose tissue by imaging in a defined patient population, alongside hormone markers, withdrawals and adverse events over a fixed study period.
A 2007 randomized trial in 412 patients with HIV and abdominal fat accumulation, over 26 weeks, reported reduced visceral fat and increased IGF-I in that population, with more withdrawals due to adverse events.
Human trial literature: A 26-week randomized trial in 412 patients reported reduced visceral fat and increased IGF-I. A specific fat compartment and patient population, not general weight loss or performance evidence.
Human trial literature: Withdrawals due to adverse events were more frequent in the treatment group. The trial medicine was not PLP’s vial or pen formulation.
Proof Line Peptides lists Tesamorelin as a vial in 10 mg and 5 mg, with pack sizes of 1, 3, 5 and 10. Prices are shown in Canadian dollars, and orders ship from Toronto by tracked Canadian service.
The matched PPB Analytical Inc. report for Tesamorelin 10 mg (report 2026030634-02, dated Mar. 27, 2026) records 100.00% purity. It documents the supplier sample sent for testing, not every shipped lot, and the original PDF is linked on this page.
Shipped lyophilized (freeze-dried) and stable at room temperature in transit. Store sealed vials in the fridge or freezer on arrival. Once reconstituted, refrigerate. Anything not right? Our guarantee covers it.
80 mg
$349.99 CAD
20 mg
$299.99 CAD
40 mg
$299.99 CAD